Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Celgene1,494 enrolled

Overview

The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.

Study Type

OBSERVATIONAL

Enrollment

1,494

Conditions

Chronic Lymphocytic Leukemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis with CLL * Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment * Age≥18 years * Willing and able to provide signed informed consent * Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Exclusion Criteria: * Participation in a clinical study in which study treatment is blinded * Patient condition is considered terminal (i.e.\<6 months to live)

Locations (165)

Outcomes

Primary Outcomes

Identify and summarize patterns in therapeutic regimens and patient outcomes

The primary objective is to 1) describe practice patterns of first line therapy regimens and subsequent therapeutic strategies in patients initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting (2) Provide insight into therapeutic regimens and therapy sequence in clinical practice as they relate to clinical outcomes in patients initiated on first-line, second-line or subsequent therapies for CLL.

Time frame: up to 8 years

Secondary Outcomes

Summarize Effectiveness of Treatment Regimens

Describe any differences in effectiveness associated with treatment regimens, including first-line regimens and subsequent therapeutic strategies in patients actively treated for CLL

Time frame: up to 8 years

Health Related Quality of Life Measures Related to Therapeutic Regimens

Describe the health-related quality of life of patients actively treated for CLL, and to explore the association of HRQoL with therapeutic regimens, sequences and clinical outcomes.

Time frame: up to 8 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

New Hope Cancer & Research Institute

Pomona, California, United States

Medical Specialists of the Palm Beaches

Atlantis, Florida, United States

University Cancer Institute

Boynton Beach, Florida, United States

Thomas Niederman, MD

Boynton Beach, Florida, United States

Pasco Hernando Oncology Associates (Kumar)

New Port Richey, Florida, United States

Phoebe Putney Memorial Hospital

Albany, Georgia, United States

Peachtree Hematology-Oncology Consultants

Atlanta, Georgia, United States

Georgia Cancer Specialists

Atlanta, Georgia, United States

US Oncology - Dublin Hematology & Oncology

Dublin, Georgia, United States

Straub Clinic and Hospital

Honolulu, Hawaii, United States

...and 155 more locations